Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3296-3301

  Cisternino, Salvatore ^a   Mercier, Claire ^a   Bourasset, Fanchon ^a   Roux, Françoise ^a   Scherrmann, Jean Michel ^a  

^a HÔPITAL FERNAND WIDAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; MESSENGER RNA; MITOXANTRONE; PRAZOSIN; VALSPODAR; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN PERFUSION; CAPILLARY ELECTROPHORESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TRANSPORT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; MALE; MICE; MICE, KNOCKOUT; MITOXANTRONE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PRAZOSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION; VINBLASTINE;

EID: 2342644918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2033     Document Type: Article

References (34)

1. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003;55:83-105.
2. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 2001;33:503-11.
3. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
4. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
5. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003;63:1339-44.
6. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 2002;62:2294-9.
7. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13: 2059-63.
8. Eisenblatter T, Galla HJ. A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 2002;293:1273-8.
9. Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003;971:221-31.
10. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003;17:2085-7.
11. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99:15649-54.
12. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 1984;247:H484-93.
13. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J Cereb Blood Flow Metab 2000;20:381-6.
14. Cistemino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res 2001;18:183-90.
15. Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM. Apparent lack of Mrp1-mediated efflux at the luminal side of mouse BBB endothelial cells. Pharm Res 2003;20:904-9.
16. Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism, Vol. 8. New York: Plenum Press, 1996. p. 285-307.
17. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-41.
18. De Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-26.
19. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABGG2). J Cell Sci 2000;113:2011-21.
20. Triguero D, Buciak J, Pardridge WM. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 1990;253: 884-91.
21. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000;57:679-86.
22. Lattera J, Goldstein GW. Brain microvessels and microvscular cells in vitro. In: Pardridge WM, editor. The blood-brain barrier cellular and molecular biology. New York: Raven Press, 1993. p. 1-24.
23. Pardridge WM. Isolated brain capillaries: an in vitro model of blood-brain barrier research. In: Pardridge WM, editor. Introduction to the blood-brain barrier. Methodology, biology and pathology. Cambridge: Cambridge University Press, 1998. p. 49-62.
24. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841-50.
25. Greenberger LM, Yang CP, Gindin E, Horwitz SB. Photoaffinity probes for the α1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 1990;265:4394-401.
26. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58:624-32.
27. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
28. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-6.
29. Diah SK, Smitherman PK, Aldridge J, et al. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res 2001;61:5461-7.
30. Rajagopal A, Pant AC, Simon SM, Chen Y. In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1. Cancer Res 2002;62:391-6.
31. Robey RW, Honjo Y, van de Laar A, et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001;1512: 171-82.
32. Özvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation J Biol Chem 2002;277:47980-90.
33. Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
34. Umbenhauer DR, Lankas GR, Pippert TR, et al. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 1997;146:88-94.